Wedbush Has Bearish Forecast for TLX FY2025 Earnings

Key Points

• Wedbush has revised its FY2025 earnings estimate for Telix Pharmaceuticals to ($0.11) per share, down from a previous forecast of $0.06.
• The company currently holds an Outperform rating from Wedbush, with a price target of $22.00 for its stock.
• Analysts have varying ratings for Telix Pharmaceuticals, with one Strong Buy, five Buy, one Hold, and one Sell rating based on the stock's performance and future outlook.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Equities researchers at Wedbush lowered their FY2025 earnings estimates for Telix Pharmaceuticals in a report issued on Tuesday, October 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.11) for the year, down from their prior forecast of $0.06. Wedbush currently has a "Outperform" rating and a $22.00 price target on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share. Wedbush also issued estimates for Telix Pharmaceuticals' FY2027 earnings at $0.39 EPS.

A number of other analysts have also recently weighed in on TLX. Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a "strong-buy" rating in a report on Monday, October 6th. Citigroup started coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They set a "buy" rating and a $22.00 target price for the company. JPMorgan Chase & Co. restated a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. UBS Group reduced their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a report on Tuesday, September 23rd. Finally, HC Wainwright reduced their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $21.00.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX opened at $11.01 on Thursday. Telix Pharmaceuticals has a 1-year low of $8.93 and a 1-year high of $30.36. The company has a 50 day moving average price of $10.33 and a 200 day moving average price of $14.20.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently modified their holdings of TLX. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals during the 1st quarter valued at $170,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $213,000. Blair William & Co. IL bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $217,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $297,000. Finally, ABC Arbitrage SA bought a new position in shares of Telix Pharmaceuticals during the 1st quarter valued at $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.